Zomedica Pharmaceuticals Corp Working Capital to Net Assets Ratio
Zomedica Pharmaceuticals Corp working capital to net assets ratio. Zomedica Pharmaceuticals Corp (ZOM) has a Working Capital to Net Assets ratio of 49.7% as of March 2025. Working capital of $65.82 Million (current assets of $73.22 Million minus current liabilities of $7.41 Million) is measured against net assets of $132.44 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check ZOM goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Zomedica Pharmaceuticals Corp (2012–2024)
Working capital to net assets ratio of Zomedica Pharmaceuticals Corp from 2012 to 2024. This chart shows how Zomedica Pharmaceuticals Corp's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of March 2025, the ratio stands at 49.7%, reflecting working capital of $65.82 Million against net assets of $132.44 Million USD. See Zomedica Pharmaceuticals Corp defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Zomedica Pharmaceuticals Corp Working Capital to Net Assets Ratio by Year (2012–2024)
Zomedica Pharmaceuticals Corp working capital to net assets ratio by year from 2012 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Zomedica Pharmaceuticals Corp from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see ZOM total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 37.0% | $72.44 Million | $195.66 Million | $81.77 Million | $9.33 Million | ▼ -0.8 pp |
| 2023 | 37.9% | $90.85 Million | $240.02 Million | $99.88 Million | $9.03 Million | ▼ -5.4 pp |
| 2022 | 43.3% | $115.69 Million | $267.39 Million | $123.50 Million | $7.81 Million | ▼ -29.1 pp |
| 2021 | 72.4% | $196.07 Million | $270.89 Million | $200.41 Million | $4.34 Million | ▼ -46.8 pp |
| 2020 | 119.1% | $60.84 Million | $51.07 Million | $62.87 Million | $2.03 Million | ▲ +132.5 pp |
| 2019 | -13.4% | $-280.74K | $2.10 Million | $1.81 Million | $2.09 Million | ▼ -54.0 pp |
| 2018 | 40.6% | $1.48 Million | $3.66 Million | $3.86 Million | $2.38 Million | ▼ -37.7 pp |
| 2017 | 78.3% | $3.43 Million | $4.39 Million | $4.26 Million | $828.74K | ▲ +9.7 pp |
| 2016 | 68.6% | $2.84 Million | $4.13 Million | $3.58 Million | $741.16K | ▼ -19.9 pp |
| 2015 | 88.5% | $3.29 Million | $3.71 Million | $3.43 Million | $146.29K | ▼ -11.5 pp |
| 2014 | 100.0% | $141.41K | $141.41K | $145.34K | $3.93K | ▲ +0.0 pp |
| 2013 | 100.0% | $206.38K | $206.38K | $211.54K | $5.16K | ▲ +18.3 pp |
| 2012 | 81.7% | $78.75K | $96.34K | $79.73K | $976.80 | — |